38 results
Page 2 of 2
8-K
EX-99.1
uxc 0asvxw
28 Apr 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-99.2
3iqdc6cpocnsy9jf8szk
4 Mar 21
Entry into a Material Definitive Agreement
4:26pm
8-K
EX-99.1
cpsw6 0pho
4 Mar 21
Entry into a Material Definitive Agreement
4:26pm
424B5
mjko gbo9
4 Mar 21
Prospectus supplement for primary offering
4:23pm
424B5
211vj
2 Mar 21
Prospectus supplement for primary offering
4:26pm
8-K
EX-99.1
hydmzh2h
24 Feb 21
Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI ® Product Revenue
4:13pm
8-K
EX-99.1
hg8 7ccg6l327
5 Nov 20
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection
4:01pm
8-K
EX-99.1
w466i 1qolm
4 Aug 20
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
4:10pm
8-K
EX-99.1
ve2hrnwr
11 May 20
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
4:24pm
424B5
f0prgmkq1nlu0ale
24 Apr 20
Prospectus supplement for primary offering
5:11pm
8-K
bu997t6h9jhbf0
31 Mar 20
Entry into a Material Definitive Agreement
9:03am
424B5
yhj38bo8hr82jc9lz7t
31 Mar 20
Prospectus supplement for primary offering
9:01am
8-K
EX-99.1
baso1e77 20mnvy73i31
28 Feb 20
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
8:32am